Nonalcoholic fatty liver disease — now referred to in medical circles as MASLD (Metabolic dysfunction-associated steatotic liver disease) — has quietly become one of the major global threats to health.
Dr. Simpson, your respectful interpretation of health science for lay readers and viewers has been such a gift, here and on TikTok. Thank you for fighting the good fight against the anti-science forces contaminating our public discourse.
I question whether the positive effects of these drugs are not only discontinued but reversed when the user chooses to stop use. Must it be a lifetime prescription to truly be effective?
Are there any studies showing that use of these drugs can result not only in pancreatitis but also pancreatic cancer? The concern is that the latter apparently is diagnosable only after it is terminal.
no evidence of that. The instance of pancreatitis in the drug are so far normal for most weight loss interventions - and so far no evidence of pancreatic cancer. In fact with decrease in inflammation - probably protective
Small point of order just so people aren’t confused. Semaglutide is not the active ingredient in the brand Zepbound. Semaglutide is the active ingredient in Ozempic and Wegovy.
Zepbound and Mounjaro contain the active ingredient called tirzepatide.
Mimics glucagon-like peptide-1 (GLP-1), which helps lower blood sugar, slow gastric emptying, and reduce appetite.
Tirzepatide (brand name: Mounjaro, Zepbound):
➤ Dual GIP and GLP-1 receptor agonist
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action seems to enhance insulin sensitivity, suppress appetite more effectively, and result in greater weight loss.
📊 2. Efficacy (Weight Loss & A1C Reduction)
Weight loss (based on clinical trials):
Semaglutide (Wegovy): ~15% average weight loss at high doses (2.4 mg/week)
Tirzepatide (Zepbound): Up to 22.5% weight loss at highest dose (15 mg/week) — currently the most effective injectable obesity drug available.
A1C reduction:
Semaglutide: ~1.5–1.8% drop
Tirzepatide: ~2.0–2.5% drop
🧪 3. FDA Approvals
Semaglutide:
Ozempic – Type 2 diabetes
Wegovy – Obesity/weight management
Tirzepatide:
Mounjaro – Type 2 diabetes
Zepbound – Obesity/weight management (approved Nov 2023)
Dr. Simpson, your respectful interpretation of health science for lay readers and viewers has been such a gift, here and on TikTok. Thank you for fighting the good fight against the anti-science forces contaminating our public discourse.
Thank you so much
I question whether the positive effects of these drugs are not only discontinued but reversed when the user chooses to stop use. Must it be a lifetime prescription to truly be effective?
Yes, it is a chronic disease -and just like people who need insulin, people need these drugs to manage those diseases.
Are there any studies showing that use of these drugs can result not only in pancreatitis but also pancreatic cancer? The concern is that the latter apparently is diagnosable only after it is terminal.
no evidence of that. The instance of pancreatitis in the drug are so far normal for most weight loss interventions - and so far no evidence of pancreatic cancer. In fact with decrease in inflammation - probably protective
Small point of order just so people aren’t confused. Semaglutide is not the active ingredient in the brand Zepbound. Semaglutide is the active ingredient in Ozempic and Wegovy.
Zepbound and Mounjaro contain the active ingredient called tirzepatide.
🔬 1. Mechanism of Action
Semaglutide (brand names: Ozempic, Wegovy):
➤ GLP-1 receptor agonist
Mimics glucagon-like peptide-1 (GLP-1), which helps lower blood sugar, slow gastric emptying, and reduce appetite.
Tirzepatide (brand name: Mounjaro, Zepbound):
➤ Dual GIP and GLP-1 receptor agonist
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action seems to enhance insulin sensitivity, suppress appetite more effectively, and result in greater weight loss.
📊 2. Efficacy (Weight Loss & A1C Reduction)
Weight loss (based on clinical trials):
Semaglutide (Wegovy): ~15% average weight loss at high doses (2.4 mg/week)
Tirzepatide (Zepbound): Up to 22.5% weight loss at highest dose (15 mg/week) — currently the most effective injectable obesity drug available.
A1C reduction:
Semaglutide: ~1.5–1.8% drop
Tirzepatide: ~2.0–2.5% drop
🧪 3. FDA Approvals
Semaglutide:
Ozempic – Type 2 diabetes
Wegovy – Obesity/weight management
Tirzepatide:
Mounjaro – Type 2 diabetes
Zepbound – Obesity/weight management (approved Nov 2023)